Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. - sprookjes - yvandenbroek - TriplyDB

Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy.

Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy.

http://www.wikidata.org/entity/Q30438880

about

A2A receptors in inflammation and injury: lessons learned from transgenic animals Purinergic signalling and diabetes Targeting inflammation in diabetes: Newer therapeutic options Recent developments in adenosine receptor ligands and their potential as novel drugs Graft versus host disease: New insights into A2A receptor agonist therapy The immunosuppressive role of adenosine A2A receptors in ischemia reperfusion injury and islet transplantation.Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.Inactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosis Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury.Activation of adenosine 2A receptors preserves structure and function of podocytes Adenosine A(2A) agonist administration improves islet transplant outcome: Evidence for the role of innate immunity in islet graft rejection.Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development.Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation.Adenosine signaling during acute and chronic disease states Autoimmunity in CD73/Ecto-5'-nucleotidase deficient mice induces renal injury From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy.CD39 modulates hematopoietic stem cell recruitment and promotes liver regeneration in mice and humans after partial hepatectomy.Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementation A(₂A) adenosine receptor (A(₂A)AR) as a therapeutic target in diabetic retinopathy.Arginase-2 mediates diabetic renal injury.Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal Injury Transcriptional analysis of infiltrating T cells in kidney ischemia-reperfusion injury reveals a pathophysiological role for CCR5.Reduced Adenosine Uptake and Its Contribution to Signaling that Mediates Profibrotic Activation in Renal Tubular Epithelial Cells: Implication in Diabetic Nephropathy.Introduction to adenosine receptors as therapeutic targets.Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.Endogenous Inhibitors of Kidney Inflammation.Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells.Cannabidiol arrests onset of autoimmune diabetes in NOD mice Enhanced A2A adenosine receptor-mediated increase in coronary flow in type I diabetic mice.Adenosine A₂A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease.Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury.New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy.Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism Reversal of Early Diabetic Nephropathy by Islet Transplantation under the Kidney Capsule in a Rat Model.Macrophages directly mediate diabetic renal injury.Activation of adenosine receptors improves renal antioxidant status in diabetic Wistar but not SHR rats CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy.Therapeutic potential of adenosine receptor antagonists and agonists.Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation.

P2860

Q24652486-0FAA1688-D5A2-475D-A5F9-16F1A391E407 Q26828574-796CC8A6-FDAF-4884-AB09-A49DD7346A41 Q26852726-2C820190-32F8-4D10-945D-3F6F92651738 Q27687253-95CAFF79-C0F2-4388-932B-832ECD6CD6E5 Q28080809-A3AFE0D4-2AF0-4D13-A0F8-3B74F567E0E6 Q30409961-0615D32D-BA8B-457B-A88D-0DD8BC33FE7C Q30423561-7A56C478-F6D4-4214-B4B7-92DBD2281036 Q30427148-8599A013-AEFB-40DF-8444-38262E628991 Q30435620-A8D68040-4927-4AB9-A9EE-2EFA80A6B971 Q30436624-493F74F7-676A-4AF8-9069-60A4D097853A Q30440549-CA3EEA2B-622E-4EF2-BC38-4EF409A76256 Q30450509-FE7C95E7-09C6-49FF-841B-9ED0CCCF2962 Q30497010-A85DC66B-121D-4F31-AB8E-4D2BF2DD9AC0 Q33615249-9505371B-45D0-4D1E-98A7-301C0FA86E3D Q34035228-C519030E-83E0-4DBE-AE58-F2688ABBF330 Q34292449-7AD32E1A-F52B-4E3C-A83F-6FE67D930311 Q34554570-D5242E51-0CBA-43AB-B983-A9495EC5E502 Q34569461-4BD3BA46-DEAF-44FE-A582-B3BD941B7E03 Q34627559-870ADBB8-858A-4FB2-912C-18E8A037619E Q34838463-9EAFAE8C-D44C-4144-840E-2BF83113E1DD Q35405005-16B464C2-1506-44E6-BFAD-6B421F09D111 Q35710293-F9233900-06F4-4B05-87D5-D908293578E7 Q35849486-4B53646F-4BBD-402E-8482-2840625B6E66 Q35903704-C439FFBC-16A1-4805-A9B9-DA64EAFD0FC0 Q36153376-436B8AE6-A58A-4293-846B-114B50956E86 Q36297539-7073084A-A2A8-490F-B5B7-D6A4904D4815 Q36458172-DC6C2C28-3F69-41E8-9D84-273D30816A9D Q36496998-1B9EF07A-C842-4FEE-8949-3AB307CB9334 Q36501954-056F3439-E7DB-4CC3-8FE7-393518895CC5 Q36510139-3CB9B100-7102-4F9D-9DC1-E55DECA325E9 Q36907484-BEA6D703-2CE9-401A-82BB-0F691BCA42EF Q37142636-BF4FF296-A609-47F4-BFD8-56720FC6610E Q37180781-B2E0360E-4256-462F-A018-B28FC3229035 Q37198831-4993E315-C61F-404C-9D77-932EF07002CB Q37306789-5481B4EC-1E7D-4609-B9C0-BCCAEDF5A8FC Q37440181-AC17E539-0F86-4B9B-BC5E-B779CBF317F7 Q37564150-EAD1E679-11A1-4604-99D8-E24B51B2404E Q37604704-86528F4C-5AD6-436F-9A06-75A942FBBD4F Q37689793-CEB0D452-BC11-4AB8-81A0-996E54549B88 Q37871350-0163886E-CD93-47E1-B7AE-A5271E9E53E7

P2860

Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy.

http://www.wikidata.org/entity/Q30438880

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Adenosine A2A receptor activat ...... njury in diabetic nephropathy.

@ast

Adenosine A2A receptor activat ...... njury in diabetic nephropathy.

@en

type

label

Adenosine A2A receptor activat ...... njury in diabetic nephropathy.

@ast

Adenosine A2A receptor activat ...... njury in diabetic nephropathy.

@en

prefLabel

Adenosine A2A receptor activat ...... njury in diabetic nephropathy.

@ast

Adenosine A2A receptor activat ...... njury in diabetic nephropathy.

@en

P1433

Q30438880-D0ACC87B-568F-444E-A1FB-F56BC0179F31

P1476

Q30438880-79575964-D153-412D-9B59-B391501FDE9E

P2093

Q30438880-01B1AD2B-6904-4FD9-BC0F-E5B37B05E2B7

Q30438880-01E0C5A9-6761-426C-A484-67DDFE426BB4

Q30438880-29074BB9-D2BD-4663-AA01-CA99B2F64FCC

Q30438880-3375DE75-79BC-45F9-913A-2E2024424CB6

Q30438880-D2252F60-7373-494D-BF09-7099424306EB

Q30438880-E861B50F-9D09-44E4-B60F-6AF81DCAA467

P2860

Q30438880-1519DA86-A44E-4515-871B-0C292247199F

Q30438880-1951B7FA-543B-4664-ADDC-76A694362D01

Q30438880-2952CF83-C3F6-468A-B6BA-4ACF24857411

Q30438880-2C44A2D2-C19A-4774-9082-3B164519EF9F

Q30438880-3970A4F0-A292-4B99-A610-DCBD40ED938E

Q30438880-3A480418-87FA-4365-9319-02B9C3F96857

Q30438880-3C766166-8B3F-4DA3-BEBB-D7C7B5B97A8A

Q30438880-47332303-91DA-4103-8A8B-9E4DCA94904B

Q30438880-545C8A51-4804-416B-952A-F607F5001FFE

Q30438880-5F301D76-905A-465E-951D-DE750FA267DF

P304

Q30438880-5609C94D-A9DC-4806-B292-2EDACB47AF72

P31

Q30438880-5454190F-8047-418D-A16F-0D7FE37F6599

P356

Q30438880-399981B4-014C-4468-92ED-7BDAD6518000

P433

Q30438880-B1E469C2-ED9B-42F0-BED4-D5D0C8C9FC9B

P478

Q30438880-02C4A4F7-9FC4-4F21-A794-F402F989C8E5

P50

Q30438880-01E9749A-EBF3-426C-B0C6-450D03723C70

P577

Q30438880-57917A57-5929-445B-853F-6D882A3F9FBE

P698

Q30438880-0816C64B-7293-4A68-B87D-B946BEEC141F

P921

Q30438880-EE7B9D39-1092-43D6-9339-B0CA5BADC450

P356

AJPRENAL.00310.2005

P1433

American Journal of Physiology - Renal Physiology

P1476

Adenosine A2A receptor activat ...... njury in diabetic nephropathy.

@en

P2093

Alaa S Awad

http://www.w3.org/2001/XMLSchema#string

Elizabeth Thu Anh Duong

http://www.w3.org/2001/XMLSchema#string

Hong Ye

http://www.w3.org/2001/XMLSchema#string

Joel Linden

http://www.w3.org/2001/XMLSchema#string

Liping Huang

http://www.w3.org/2001/XMLSchema#string

W Kline Bolton

http://www.w3.org/2001/XMLSchema#string

P2860

Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin

Expression of podocyte-associated molecules in acquired human kidney diseases

Transforming growth factor beta in tissue fibrosis

RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis

Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies

Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists.

Design, synthesis, and evaluation of novel A2A adenosine receptor agonists.

Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection.

Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats.

Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells.

P304

F828-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPRENAL.00310.2005

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

290

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16332931

http://www.w3.org/2001/XMLSchema#string

P921